Details of the Drug Combination

General Information of Drug Combination (ID: DCDQ5S6)

• Drug Combination Name: LY03004 + Brincidofovir
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  LY03004 (DME5TUR): N.A.
  Brincidofovir (DMS0PND): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 7.44
  Bliss Independence Score: 7.44
  Loewe Additivity Score: 8.38
  LHighest Single Agent (HSA) Score: 8.39

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094.